Actinium Pharmaceuticals: Far Enough Along For A Small Bet

About: Actinium Pharmaceuticals, Inc. (ATNM)
by: Elle Investments
This article is exclusive for subscribers.
Elle Investments
Long/Short Equity, Value, Contrarian

Their targeted approach to bone marrow transplant conditioning has shown early signs of significantly improving on the poor outcomes seen with current non-targeted therapies.

The early nature of the data and the high likelihood of several future rounds of dilutive financing prevent this from being a top pick.

Still, the promising results thus far justify a small bet.

Actinium Pharmaceuticals (NYSE:ATNM) is a clinical stage biotech developing treatments in the growing field of targeted radiotherapies. All except one of their candidates are in phase 2 or below, and their platform is